The history of the erectile dysfunction drug presents a intricate picture for investors. While the initial introduction generated substantial gains, the lapse of its exclusive rights opened the avenue to cheaper alternatives, dramatically reducing revenue. This presents a unique risk for firms relying on similar blockbuster offerings, suggesting th

The legacy of Viagra, and its creator copyright, presents a complex case study for investors. At first a blockbuster drug, yielding billions in income, its patent expiration created a deluge of knock-off medications, significantly diminishing its market share . While specific pharmaceutical companies may seek to capitalize on male sexual dysfunctio